Skip to main content
SpringerLink
Log in

Role of ACE Inhibitors in Patients with Diabetes Mellitus

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The adjective ‘epidemic’ is now attributed to the rapidly growing number of patients with diabetes mellitus, mainly type 2, and the specific complications linked to this disorder. Provided they are recognised early enough, these different complications can be treated; in some patients the evolutive course of these complications can be slowed or even stopped. Furthermore, some recent observations suggest that specific tissular lesions may be prevented or even reversed.

Although glycaemic control is essential, other therapeutic measures that must also be taken include those to control blood pressure and to lower lipid levels. Of the agents available to control the complications of diabetes mellitus, cardiovascular drugs, and particularly ACE inhibitors, have a pre-eminent place. Experimental and epidemiological data suggest that activation of the renin-angiotensin-aldosterone system plays an important role in increasing in the micro- and macrovascular complications in patients with diabetes mellitus. Not only are ACE inhibitors potent antihypertensive agents but there is a growing body of data indicating that also they have a specific ‘organ-protective’ effect. For the same degree of blood pressure control, compared with other antihypertensive agents, ACE inhibitors demonstrate function and tissue protection of considered organs. ACE inhibitors have been reported to improve kidney, heart, and to a lesser extent, eye and peripheral nerve function of patients with diabetes mellitus. These favourable effects are the result of inhibition of both haemodynamic and tissular effects of angiotensin II. Finally, there are a growing number of arguments favouring the use of ACE inhibitors very early in patients with diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications. Estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl. 5: 1–15

    Google Scholar 

  2. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795–808

    Article  PubMed  CAS  Google Scholar 

  3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381–9

    Article  Google Scholar 

  4. Turner RC, Millns H, Neil HAW, et al. for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823–8

    PubMed  CAS  Google Scholar 

  5. Fioretto P, Steffes MW, Sutherland DES, et al. Reversal of diabetic nephropathy by pancreas transplantation. N Engl J Med 1998; 339: 69–75

    Article  PubMed  CAS  Google Scholar 

  6. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319–25

    Google Scholar 

  7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13

    Article  Google Scholar 

  8. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62

    Article  PubMed  CAS  Google Scholar 

  9. Gaede P, Vedel P, Parving H, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617–22

    Article  PubMed  CAS  Google Scholar 

  10. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmalogical amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–30

    Article  PubMed  CAS  Google Scholar 

  11. Anderson S, Rennke HG, Garcia DL, et al. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526–36

    Article  PubMed  CAS  Google Scholar 

  12. Björk S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 471–4

    Article  Google Scholar 

  13. Laffel LMB, McGill JB, Bans DJ. The beneficial effect of angiotensin-Converting Enzyme Inhibition with Captopril on diabetic nephropathy in Normotensive IDDM patients with Microalbuminuria. Am J Med 1995; 99: 497–504

    Article  PubMed  CAS  Google Scholar 

  14. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–92

    Article  Google Scholar 

  15. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of Angio-tensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62

    Article  PubMed  CAS  Google Scholar 

  16. Kasiske BL, Kalil RSN, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–38

    PubMed  CAS  Google Scholar 

  17. Bohlen L, Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S–92S

    PubMed  CAS  Google Scholar 

  18. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996; 156: 286–9

    Article  PubMed  CAS  Google Scholar 

  19. Cordonnier DJ, Pinel N, Barro C, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253–63

    PubMed  CAS  Google Scholar 

  20. Cordonnier DJ. Glomerular involvement in type 2 diabetes. Is it all glomerulosclerosis [editorial]? Nephrol Dial Transpl 1996; 11: 936–8

    Article  CAS  Google Scholar 

  21. Mosconi L, Ruggenenti P, Perna A, et al. Nitrendipine and Enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes. Kidney Int 1996; 49 Suppl. 55: 91–3

    Google Scholar 

  22. Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy [editorial]. Lancet 2000; 355: 253–9

    Article  Google Scholar 

  23. Sato H, Iwano M, Akai Y, et al. Increased excretion of urinary transforming growth factor βl in patients with diabetic nephropathy. Am J Nephrol 1988; 18: 490–94

    Article  Google Scholar 

  24. Baricos WH, Cortez SL, Deboisblanc M, et al. Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 790–5

    PubMed  CAS  Google Scholar 

  25. Ma J, Nishimura H, Fogo A, et al. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998; 53: 937–44

    Article  PubMed  CAS  Google Scholar 

  26. Sharma K, Eltayeb BO, McGowan TA, et al. Captopril-induced reduction of serum levels of transforming growth factor-β 1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34: 818–23

    Article  PubMed  CAS  Google Scholar 

  27. Wang SN, Hirschberg R. Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy. Nephrol Dial Transplant 1999; 14: 2072–4

    CAS  Google Scholar 

  28. Abbate M, Zoja C, Rottoli D, et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 1999; 10: 790–5

    Google Scholar 

  29. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627–37

    Article  PubMed  CAS  Google Scholar 

  30. Morelli E, Loon N, Meyer TW, et al. Effects of converting enzyme inhibitors on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76–82

    Article  PubMed  CAS  Google Scholar 

  31. Hansson L, Lindholm L, Nisaken L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–16

    Article  PubMed  CAS  Google Scholar 

  32. Capes SE, Gerstein HC, Negassa A, et al. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000; 23: 377–80

    Article  PubMed  CAS  Google Scholar 

  33. Cohn JN. Drug therapy: the management of chronic heart failure. N Engl J Med 1996; 335: 490–8

    Article  PubMed  CAS  Google Scholar 

  34. Delcourt C, Villatte-Cathelineau B, Vauzelle-Kervroedan F, et al. Clinical correlates of advanced retinopathy in type II diabetic patients: Implications for screening. J Clin Epidemiol 1996; 49: 679–85

    Article  PubMed  CAS  Google Scholar 

  35. American Diabetes Association: diabetic retinopathy. Diabetes Care 1998; 21 Suppl. 1: 47–9

    Google Scholar 

  36. Chaturvedi N, Sjolie A, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28–31

    Article  PubMed  CAS  Google Scholar 

  37. Barnett AH. The heart outcome protection evaluation (HOPE) study: relevance to ophtalmological practice? Eye 2000; 14: 1–2

    Article  PubMed  Google Scholar 

  38. Larsen M, Hommel E, Parving HH, et al. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophtalmol 1990; 228: 505–9

    Article  CAS  Google Scholar 

  39. Jackson WE, Holmes DL, Garg SK, et al. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophtalmol 1992; 24: 99–103

    CAS  Google Scholar 

  40. Feman SS, Mericle RA, Reed GW, et al. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci 1993; 305: 280–4

    Article  PubMed  CAS  Google Scholar 

  41. Danser AH, Derkx FH, Admiraal PJ, et al. Angiotensin levels in the eye. Invest Ophtalmol Vis Sci 1994; 35: 1008–18

    CAS  Google Scholar 

  42. Williams B. Angiotensin II, VEGF and diabetic retinopathy [letter]. Lancet 1998; 351; 836–7

    Google Scholar 

  43. Forrest KYZ, Maser RE, Pambianco G, et al. Hypertension as a risk factor for diabetic neuropathy. Diabetes 1997; 46: 665–70

    Article  PubMed  CAS  Google Scholar 

  44. Malik RA. The pathology of human diabetic neuropathy. Diabetes 1997; 46 Suppl. 2: S50–53

    PubMed  CAS  Google Scholar 

  45. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streopozotocin-diabetic rats. Diabetologia 1992; 35: 12–18

    Article  PubMed  CAS  Google Scholar 

  46. Al-Memar A, Wimalaratna HSK, Millward BA. Lisinopril improves nerve function in insulin-dependant diabetic patients with neuropathy: a preferential effect on small fibres. Diabet Med 1996; 13(S38): 90

    Google Scholar 

  47. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978–81

    Article  PubMed  CAS  Google Scholar 

  48. Jackson EK, Garrison JC. Renin and angiotensin. In: Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. USA: Mc Graw-Hill, 1996: 733–58

    Google Scholar 

  49. Seghieri G, Yin W, Boni C, et al. Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type II diabetic patients. Diabet Med 1992; 9: 732–8

    Article  PubMed  CAS  Google Scholar 

  50. Bak J, Gerdes L, Sorensen N, et al. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 1992; 92: 69–72

    Article  Google Scholar 

  51. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868–73

    Article  PubMed  CAS  Google Scholar 

  52. New JP, Bilous RW. Insulin sensitivity in type II diabetic patients treated with insulin. Diabet Med 2000; 17: 134–40

    Article  PubMed  CAS  Google Scholar 

  53. Herings RM, De Boer A, Strieker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995; 345: 1195–8

    Article  PubMed  CAS  Google Scholar 

  54. Keilani T, Schimeter WA, Levin ML, et al. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 1993; 118: 246–254

    PubMed  CAS  Google Scholar 

  55. Courrèges JP, Bacha J, Aboud E. Prevalence and profile of reno vascular disease in diabetic type 2 with severe hypertension. J Hypertens 1997; 15: 1348–51

    Article  Google Scholar 

  56. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 1996; 19: 1051–61

    Article  PubMed  CAS  Google Scholar 

  57. Le Pen Cl, Petitjean Ph, Levy P, et al. L’évaluation économique de l’apport du captopril dans le traitement de la néphropathie diabétique: une approche coût-efficacité. Nephrol 1997; 17: 321–6

    Google Scholar 

  58. Lewis V, Kloer P, Prasad N, et al. The HOPE study and diabetes [letter]. Lancet 2000; 355: 1182

    Article  PubMed  CAS  Google Scholar 

  59. Fegan G, Ward D, Clarke L, et al. The HOPE study and diabetes [letter]. Lancet 2000; 355: 1182–3

    Article  PubMed  CAS  Google Scholar 

  60. Soma J, Saito T, Taguma Y, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11: 690–9

    PubMed  CAS  Google Scholar 

  61. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in patients of proteinuric insulin dependent diabetics. BMJ 1987; 295: 515–7

    Article  PubMed  CAS  Google Scholar 

  62. Pettitt DJ, Saad MF, Benett PH, et al. Familial predisposition to renal disease in two generations of pima indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 438–43

    Article  PubMed  CAS  Google Scholar 

  63. Fogarty DG, Rich SS, Hanna L, et al. Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int 2000; 57: 250–57

    Article  PubMed  CAS  Google Scholar 

  64. Cambien F. The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction. Clin Genet 1994; 46: 94–101

    Article  PubMed  CAS  Google Scholar 

  65. Hsieh MC, Lin SR, Hsieh TJ, et al. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant 2000; 15: 1008–13

    Article  PubMed  CAS  Google Scholar 

  66. Marre M, Jeunemaître X, Gallois T, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin dependent diabetes: Génétique de la néphropathie diabétique (GENEDIAB) study group. J Clin Invest 1997; 99: 1585–95

    Article  PubMed  CAS  Google Scholar 

  67. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta analysis of association of insertion/deletion polymorphism of angiotensin I converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47–53

    Article  PubMed  CAS  Google Scholar 

  68. Esnault V. Renoprotective properties of angiotensin-converting enzyme inhibitors: proofs and limits? [letter]. Nephron 2000; 85: 183–4

    Article  PubMed  CAS  Google Scholar 

  69. Bos E, De Zeeuw D, Parving HH, et al. Role of patients factors in therapy resistance to antiproteinuric therapy in non diabetic and diabetic nephropathy. Kidney Int 2000; 57 Suppl. 75: S32–7

    Article  Google Scholar 

  70. Anonymous. Should all type1 diabetic patient with microalbum-inuria receive an ACE Inhibitor? Ann Intern Med 2001; 134: 370–9

  71. Pitt B, Poole-Wilson A, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7

    Article  PubMed  CAS  Google Scholar 

  72. Morgensen CE, Neldam S, Tikkanen I. Randomised controlled trial of dual blockade of renin-angiotensin system patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321(7274): 1440–4

    Article  Google Scholar 

  73. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60

    Article  PubMed  CAS  Google Scholar 

  74. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–9

    Article  PubMed  CAS  Google Scholar 

  75. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding was received for the preparation of this article. No conflict of interest.

Author information

Authors and Affiliations

  1. Service de Néphrologie, Centre Hospitalier Universitaire de Grenoble, BP 217X, F38043, Grenoble Cedex, France

    Daniel J. Cordonnier & Philippe Zaoui

  2. Service de Diabétologie et Endocrinologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France

    Serge Halimi

Authors
  1. Daniel J. Cordonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Zaoui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serge Halimi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Cordonnier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cordonnier, D.J., Zaoui, P. & Halimi, S. Role of ACE Inhibitors in Patients with Diabetes Mellitus. Drugs 61, 1883–1892 (2001). https://doi.org/10.2165/00003495-200161130-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200161130-00001

Keywords

Search

Navigation